BlueBox Asset Management published a manager commentary from portfolio manager Mark Dainty regarding the biotech sector in August 2026, highlighting the approval of Revolution Medicines Rasonque and Moderna/Merck's personalized cancer vaccine results.

Public source

Publisher name

Public post

📈 Precision Medicine: Another Strong Month! 🧬 Here comes the August 2026 manager commentary from BlueBox Asset Management Precision Medicine lead portfolio manager, Ma…

Log in to read the full post

Company

BlueBox Asset Management

Offering our Clients the Best Long-Term Thematic Investment Funds

Industry
Financial Services
Location
Geneva, CH
Company size
11–50 employees

About BlueBox Asset Management

BBAM was formed in 2018 as a partnership between Blue Box Wealth Management and William de Gale, having just left BlackRock after 20 years investing technology equities and a decade running BlackRock's offshore global technology fund, BGF World Technology. The BlueBox Global Technology Fund was launched in March 2018, continuing William's very successful strategy of focusing principally on companies that are enabling the direct connection of computer systems to the real world - this Direct Connection lies behind everything that is currently exciting in technology. As the Fund grows, the company does too. BlueBox has since doubled in size and launched two more funds: Islamic Global Technology and Precision Medicine. We continue to fulfil our vision of offering our clients the best long-term thematic investment funds.

See more

Latest activity

4 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.